Transcriptionally Targeted and CPG-free Plasmid for Theranostic Gene Therapy
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
Hepatocellular carcinoma (HCC)
Modality
Gene Therapy
Mechanism
Transcriptionally targeted CpG-free plasmid gene therapy (theranostic)
Target
—
rNPV Envelope
Low
-$60.2M
costs +25% · peak −25%
Base
-$45.9M
cumulative PoS 1.9%
High
-$31.7M
costs −25% · peak +25%
Cell/gene-therapy cost and duration norms with an extended, expensive preclinical block because the inventive core is a delivery platform (CpG-free plasmid + PBAE 536 nanoparticle) that still needs GLP toxicology, biodistribution, and CMC scale-up beyond the published orthotopic-xenograft data (Vaughan 2022). Phase 2/3 PoS are held deliberately low: the closest mechanism-class clinical precedent (BC-819/inodiftagene) failed Phase 2 for futility, and adenoviral HSV-TK/GCV in HCC (NCT00844623) showed safety but no registrational efficacy — transcriptionally targeted suicide-gene plasmids have a poor clinical translation record. Cumulative LoA ≈ 1.9%, consistent with a preclinical, high-translational-risk asset.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.60
Modality fit · 30%
0.74
Whitespace · 30%
0.50
Composite 0.612 — composite-score rank #24 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#41) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
Inodiftagene vixteplasmid / BC-819 (H19-DTA) (Anchiano Therapeutics; lic. Hebrew University) — transcriptionally targeted cytotoxic-gene DNA plasmid
Closest mechanism-class precedent: a non-viral double-stranded DNA plasmid encoding a cytotoxic gene (diphtheria toxin A) under a tumor-selective oncofetal promoter (H19), the exact 'transcriptionally targeted plasmid that kills tumor cells' archetype this JHU asset embodies. CAUTIONARY, NOT LIVE: Anchiano discontinued the pivotal Phase 2 Codex study in BCG-unresponsive NMIBC on 2019-11-15 for futility (3/16 = 19% CR; low probability of clearing the pre-set efficacy bar) and the company reverse-merged into Chemomab in March 2021. It is the single best comparator for both the mechanism and the failure-mode risk of transcriptionally targeted suicide-gene plasmids.
Criteria 1 (same mechanism class: transcriptionally targeted cytotoxic-gene DNA plasmid) and Criteria 4 (same non-viral plasmid modality). Cautionary precedent only — status: discontinued Phase 2, 2019; sponsor merged 2021.
NWRD06 (Newish Technology, Beijing) — DNA plasmid for HCC after curative resection
The most directly on-indication active comparator: a plasmid-DNA therapeutic specifically developed for hepatocellular carcinoma in the post-resection adjuvant setting. A Phase I safety/immunogenicity study (NCT06088459) and a Phase II efficacy study (NCT07324304, initiated 2025-12-08, primary completion 2028) establish a contemporary, real, in-clinic regulatory and trial-design pathway for non-viral plasmid DNA in HCC, anchoring stage durations and feasibility for this asset's eventual clinical path.
Criteria 2 (same indication, HCC + same non-viral plasmid modality, in active clinical development) and Criteria 3 (regulatory/trial-design anchor for plasmid DNA in HCC).
AFP-promoter HSV-tk / ganciclovir suicide gene therapy for HCC (HVJ-liposome delivery; Ido/Kaneko et al., academic) — transcriptionally targeted suicide-gene precedent
Direct mechanism + target-promoter precedent for the exact cargo this asset delivers: HSV thymidine kinase driven by an alpha-fetoprotein (AFP) promoter, with ganciclovir-mediated killing, shown to inhibit hepatic HCC tumor growth in SCID mice (PMID 11402306). Establishes that AFP-restricted HSV-tk/GCV is a validated preclinical concept in HCC and frames the translational gap (no AFP-tk program has reached registration). The JHU asset's differentiation is the completely CpG-free plasmid + biodegradable PBAE nanoparticle delivery, not the suicide-gene biology itself.
Criteria 1 (same cargo mechanism and same tumor-selective AFP promoter) and Criteria 2 (same indication, HCC). Academic preclinical precedent — not a commercial program.
Adenoviral HSV-TK + ganciclovir suicide gene therapy for HCC (NCT00844623; academic Phase I)
Clinical-stage suicide-gene-therapy precedent in HCC: intratumoral HSV-TK vector followed by systemic ganciclovir, completed Phase I with a favorable safety profile but no registrational efficacy signal. Anchors the safety expectation and the translational ceiling for HSV-TK/GCV in HCC and bounds the realistic clinical PoS for any new TK-suicide approach — a viral-vector delivery comparator against which this asset's non-viral, transcriptionally targeted, theranostic differentiation is positioned.
Criteria 1 (same suicide-gene mechanism) and Criteria 2 (same indication, HCC; clinical-stage). Delivery-modality contrast (viral vs this asset's non-viral nanoparticle).
Nexavar (sorafenib, Bayer/Onyx) — first-line systemic HCC standard of care
Launched systemic-HCC therapeutic used purely as an indication-level revenue ceiling and standard-of-care reference — NOT a mechanism comparator (it is an oral multikinase inhibitor, not gene therapy). HCC-specific revenue for sorafenib historically ran in the few-hundred-million-dollars range (its global sales were blended with renal cell carcinoma), illustrating that even the dominant first-line systemic HCC drug for a decade did not generate blockbuster HCC-only revenue — a sober anchor for any HCC asset's peak.
Criteria 2 (same indication, HCC, launched) used strictly as an indication-level revenue ceiling. Explicitly NOT a modality/mechanism match — SoC anchor only.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $22.0M | 30 mo | 40.0% | [0] [1] [2] |
| Phase I | $60.0M | 18 mo | 55.0% | [3] [4] |
| Phase II | $120.0M | 30 mo | 28.0% | [3] [5] |
| Phase III | $260.0M | 42 mo | 38.0% | [3] [5] |
| NDA/BLA Review | $15.0M | 12 mo | 80.0% | [5] |
Multiplier handling: Eligible multipliers (orphan_or_expedited_pathway, biomarker_AFP_enrichment) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$350.0M peak · WACC 15.0%
Peak revenue. Modeled as a partnership/licensing economic frame, not a standalone product peak: this is an enabling delivery platform whose value to JHU is licensing royalties + milestones, not full product revenue capture. The HCC indication ceiling is modest — even sorafenib, the dominant first-line systemic HCC drug for a decade, generated only a few hundred million dollars in HCC-attributable revenue — and a transcriptionally targeted suicide-gene therapy would launch into a salvage/locoregional niche behind atezolizumab-bevacizumab and TKIs. $350M reflects an illustrative successful-program peak for the delivered therapeutic; the JHU academic owner would realize a 5–15% royalty plus milestones on that, not the headline figure. The number exists for cohort rNPV-envelope consistency only.
WACC. 15% reflects a preclinical, non-viral gene-delivery platform with no in-human data, an unproven clinical mechanism class (transcriptionally targeted suicide-gene plasmids have failed in the clinic), and platform-licensing rather than standalone-equity economics — above the 12–13% mainstream-therapeutic band.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$45.9M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$153.3M
P25
-$67.3M
P50 (median)
-$25.4M
P75
-$14.1M
P95
-$7.6M
Prob ≥ 0
1.3%
Comparable launch curves
Revenue trajectories of named comparators
Nexavar (sorafenib, Bayer/Onyx) — first-line systemic HCC standard of care
Launched 2007 · peak $950.0M (estimated)
Evidence register
7 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
Asset identity, mechanism, and preclinical efficacy (CpGf-AFP-sr39 PBAE nanoparticle; 62% tumor reduction in orthotopic HCC xenografts) stage_profile.preclinical.pos | Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma (Vaughan, Green et al., Science Advances 2022) peer_review | 2022-07-20 | high |
Granted composition-of-matter patent confirming the asset is a defined plasmid/delivery invention (expiry 2041) funding_path_archetype | US11697804B2 — Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy (Google Patents) regulatory | 2023-07-11 | high |
JHTV public listing — stage of development is preclinical (in vitro HCC cell lines + mouse models; 'more studies should be conducted') stage_profile.preclinical.duration_months | Johns Hopkins Technology Ventures — Technology 34787 (Case ID C15177) company_filing | 2019-07-02 | high |
Mechanism-class cautionary precedent — transcriptionally targeted cytotoxic-gene plasmid (BC-819) failed pivotal Phase 2 for futility stage_profile.phase_2.pos | Anchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in NMIBC (GlobeNewswire) company_filing | 2019-11-15 | high |
On-indication active plasmid-DNA HCC clinical program anchoring trial-design feasibility (Phase II initiated 2025) stage_profile.phase_3.duration_months | NWRD06 DNA Plasmid for HCC After Curative Resection (ClinicalTrials.gov NCT07324304) trial_disclosure | 2025-12-08 | high |
Clinical-stage HSV-TK/GCV suicide gene therapy in HCC — safety established, no registrational efficacy stage_profile.phase_1.pos | TK-based Suicide Gene Therapy for Hepatocellular Carcinoma (ClinicalTrials.gov NCT00844623) trial_disclosure | 2009-02-16 | medium |
AFP-promoter HSV-tk/GCV is a validated preclinical concept in HCC (target-promoter precedent for this asset's cargo) comparators[2] | HVJ-liposome-mediated transfection of HSVtk gene driven by AFP promoter inhibits hepatic tumor growth of HCC in SCID mice (PubMed 11402306) peer_review | 2001-06-01 | medium |
Thesis
Why this asset earns its rank
This JHU invention is best understood as an enabling non-viral gene-delivery platform, not a single finished drug. The inventive core is a completely CpG-free DNA plasmid paired with a biodegradable poly(beta-amino-ester) (PBAE 536) polymeric nanoparticle; the published embodiment (Vaughan, Green et al., Science Advances 2022) places a mutant HSV-1 sr39 thymidine kinase suicide gene under a CpG-free alpha-fetoprotein (AFP) promoter, so killing (via ganciclovir) and PET imaging (via 18F-FHBG) are both restricted to AFP-producing HCC cells — a genuine theranostic, tumor-restricted construct that reduced orthotopic HCC xenograft size by 62% in mice. It remains strictly preclinical (cell lines + mouse models; the inventors themselves state 'more studies should be conducted'), with a granted composition-of-matter patent (US 11,697,804 B2, expiry 2041). Because the durable asset is the CpG-free-plasmid-plus-PBAE delivery system rather than the sr39/AFP cargo, it is classified enabling_technology with a partnership/licensing value path; the rNPV envelope below is shown only for cohort consistency, not as the decision criterion.
The comparator economics are deliberately sobering. BC-819 / inodiftagene is the closest mechanism-class precedent — a transcriptionally targeted cytotoxic-gene plasmid — and it failed its pivotal Phase 2 for futility in 2019 (sponsor since merged), while clinical-stage HSV-TK/GCV suicide gene therapy in HCC (NCT00844623) showed safety but never registrational efficacy; NWRD06 (Newish) is the lone active on-indication plasmid-DNA HCC program and only entered Phase II in late 2025. HCC itself is a modest revenue ceiling — even sorafenib, the decade-long first-line systemic standard, generated only a few hundred million dollars of HCC-attributable revenue. The engine result is -$60.2M to -$31.7M, with a base rNPV of -$45.9M and cumulative PoS of 1.9%; that spread reflects a high-translational-risk preclinical platform whose academic owner would realize royalties and milestones, not full product peak. The verdict: a credible, well-characterized theranostic delivery platform that earns its rubric rank on gene-therapy modality_pos, high IRA exposure, and clinical relevance in a high-mortality cancer — not on being a standalone-fundable product. Partnership_candidate is the honest archetype: the right path is licensing the CpG-free/PBAE delivery system to a developer with HCC clinical infrastructure, because the mechanism-class clinical track record makes solo VC equity hard to defend at this stage.
Key risks
Asset-specific, not generic biotech risks
- Asset-class reality: this is a delivery platform plus one cargo configuration, not a clinic-ready single drug. Valuing it as a standalone therapeutic overstates it; the realistic value path is platform licensing (royalties + milestones), which is why it is classed partnership_candidate, not vc_fundable.
- Mechanism-class clinical track record is poor: the nearest precedent, BC-819 (transcriptionally targeted cytotoxic-gene plasmid), failed pivotal Phase 2 for futility (3/16 CR), and adenoviral HSV-TK/GCV in HCC reached only Phase I safety — no transcriptionally targeted suicide-gene therapy has been registered, so Phase 2/3 PoS is held low.
- Delivery is the unproven crux: systemic PBAE-nanoparticle plasmid delivery achieving tumor-restricted, therapeutically sufficient expression in a cirrhotic human liver is shown only in orthotopic mouse xenografts; nonviral plasmid transfection efficiency and durability in human HCC is the dominant translational risk.
- Indication ceiling is modest and crowded: front-line HCC is now atezolizumab-bevacizumab plus TKIs; a suicide-gene therapy would enter a salvage/locoregional niche, and even sorafenib's HCC-attributable revenue was only a few hundred million — a partnership economic frame, not a blockbuster.
- Theranostic regulatory complexity: the 18F-FHBG PET companion-imaging component adds a radiopharmaceutical/diagnostic regulatory path on top of the therapeutic, increasing CMC and trial-design burden for any licensee.